As of April 4, 2026, TG Therapeutics Inc has a Discounted Cash Flow (DCF) derived fair value of $64.73 per share. With the current market price at $33.53, this represents a potential upside of 93.1%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $25.94 |
| DCF Fair Value (10-year) | $64.73 |
| Potential Upside (5-year) | -22.6% |
| Potential Upside (10-year) | 93.1% |
| Discount Rate (WACC) | 8.4% - 11.6% |
Revenue is projected to grow from $616 million in 12-2025 to $5804 million by 12-2035, representing a compound annual growth rate of approximately 25.1%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2025 | 616 | 87% |
| 12-2026 | 648 | 5% |
| 12-2027 | 925 | 43% |
| 12-2028 | 1337 | 45% |
| 12-2029 | 1862 | 39% |
| 12-2030 | 2524 | 36% |
| 12-2031 | 3109 | 23% |
| 12-2032 | 3742 | 20% |
| 12-2033 | 4447 | 19% |
| 12-2034 | 5173 | 16% |
| 12-2035 | 5804 | 12% |
Net profit margin is expected to improve from 73% in 12-2025 to 21% by 12-2035, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2025 | 447 | 73% |
| 12-2026 | 115 | 18% |
| 12-2027 | 171 | 18% |
| 12-2028 | 256 | 19% |
| 12-2029 | 370 | 20% |
| 12-2030 | 517 | 20% |
| 12-2031 | 641 | 21% |
| 12-2032 | 776 | 21% |
| 12-2033 | 927 | 21% |
| 12-2034 | 1085 | 21% |
| 12-2035 | 1224 | 21% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 1% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2026 | 2 |
| 12-2027 | 4 |
| 12-2028 | 8 |
| 12-2029 | 13 |
| 12-2030 | 19 |
| 12-2031 | 26 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 44 |
| Days Inventory | 259 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2026 | 148 | 4 | 8 | (89) | 225 |
| 2027 | 220 | 5 | 12 | 129 | 74 |
| 2028 | 330 | 8 | 17 | 113 | 192 |
| 2029 | 474 | 11 | 24 | 99 | 339 |
| 2030 | 662 | 16 | 33 | 199 | 414 |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 25.94 | -22.6% |
| 10-Year DCF (Growth) | 64.73 | 93.1% |
| 5-Year DCF (EBITDA) | 31.98 | -4.6% |
| 10-Year DCF (EBITDA) | 66.52 | 98.4% |
Is TG Therapeutics Inc (TGTX) a buy or a sell? TG Therapeutics Inc is definitely a buy. Based on our DCF analysis, TG Therapeutics Inc (TGTX) appears to be significantly undervalued with upside potential of 93.1%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider a strong buy at the current market price of $33.53.